Airsculpt Technologies, Inc. Stock Price, News & Analysis

AirSculpt Technologies (NASDAQ:AIRS), a premium body contouring provider, reported Q2 2025 results showing revenue decline of 13.7% to $44.0 million compared to Q2 2024. The company posted a net loss of $0.6 million, improved from a $3.2 million loss in Q2 2024. Case volume decreased by 14.1% to 3,392 cases.

The company announced two strategic initiatives: a pilot program for skin tightening services targeting GLP-1 users, and expanded financing options. Additionally, AirSculpt reduced its debt by $16 million following a successful common stock offering in June 2025.

The company maintained its full-year 2025 guidance of $160-170 million in revenue and $16-18 million in Adjusted EBITDA. CFO Dennis Dean announced his retirement but will remain until a successor is appointed.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its second quarter 2025 financial results announcement for Friday, August 1, 2025. The company will release results before market open, followed by a conference call at 8:30 a.m. Eastern Time.

Investors can access the conference call through multiple channels, including toll-free domestic (1-877-407-9716) and international (1-201-493-6779) numbers with conference ID 13754561. A live webcast will be available on the company's investor relations website, with the replay accessible for approximately 90 days.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has announced a voluntary $10.0 million prepayment of its term loan debt using cash from a recent stock offering. The company successfully completed an offering of 3,634,000 common shares, generating net proceeds of approximately $13.8 million. Following the offering, AirSculpt's total outstanding shares increased to 62,436,670. The company plans to pay the remaining $2.9 million principal on its revolving credit facility by June 16, 2025, which will maintain full availability of $5.0 million. Management stated they don't anticipate needing additional material capital raises this year, assuming stable macroeconomic conditions.

AirSculpt Technologies, a provider of premium body contouring procedures, has successfully closed its previously announced public offering of 3,160,000 shares of common stock, with underwriters fully exercising their option for an additional 474,000 shares. The offering generated approximately $13.8 million in proceeds after estimated expenses. Leerink Partners served as the sole bookrunner. The company plans to use the majority of proceeds to prepay a portion of its outstanding debt under its existing credit agreement, with the remainder allocated for general corporate purposes, working capital, and business opportunities. The offering was conducted under a shelf registration statement that became effective on March 24, 2025.

AirSculpt Technologies (NASDAQ:AIRS), a national provider of premium body contouring procedures, has announced the pricing of its public offering of 3,160,000 common stock shares at $3.80 per share, aiming to raise $12.0 million before expenses. The company has granted the underwriter, Leerink Partners, a 30-day option to purchase up to 474,000 additional shares at the same price. The offering is expected to close around June 11, 2025. AirSculpt plans to use most of the proceeds to prepay a portion of its outstanding debt under its existing credit agreement, with the remainder allocated for general corporate purposes, including working capital and business opportunities.

AirSculpt Technologies (NASDAQ:AIRS), a premium body contouring procedures provider, has announced a public offering of 3,160,000 shares of common stock, with an additional 30-day option for underwriters to purchase up to 474,000 shares. Vesey Street Capital Partners, the company's largest stockholder, has expressed interest in purchasing up to $4.0 million in shares, though this is not a binding commitment. The company plans to use the proceeds to prepay a portion of its outstanding debt under its existing credit agreement and for general corporate purposes. Leerink Partners is serving as the sole bookrunner for the offering, which is being conducted under a shelf registration statement that became effective on March 24, 2025.

AirSculpt Technologies (NASDAQ:AIRS) reported Q1 2025 results showing significant declines across key metrics. Revenue dropped 17.3% to $39.4 million from $47.6 million in Q1 2024, while case volume decreased 17.9% to 3,076 cases. The company posted a net loss of $2.8 million compared to a $6.0 million profit in the prior year, and Adjusted EBITDA fell to $3.8 million from $7.3 million. Despite challenges, CEO Yogi Jashnani highlighted progress in cost reduction initiatives and new marketing strategies. The company provided FY2025 guidance projecting revenue of $160-170 million and Adjusted EBITDA of $16-18 million. AirSculpt is piloting skin tightening as a standalone offering and implementing expanded financing options to drive growth. The company maintained $5.6 million in cash and remained compliant with bank covenants.

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025. The company will release results before market open, followed by a conference call at 8:00 a.m. Eastern Time.

Investors can join the conference call via telephone by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13753206. Alternatively, a live webcast will be available through the investor relations section of AirSculpt's website, with replay access for approximately 90 days.

AirSculpt Technologies (NASDAQ:AIRS) reported challenging fourth quarter and full year 2024 results, showing significant declines across key metrics. Q4 revenue dropped 17.7% to $39.2 million, with case volume declining 16.7% to 3,064 cases. The company posted a Q4 net loss of $5.0 million.

For full year 2024, revenue decreased 7.9% to $180.4 million, with case volume falling 6.0% to 14,036. Net loss widened to $8.3 million from $4.5 million in 2023, while Adjusted EBITDA declined to $20.7 million from $43.2 million.

The company has implemented a cost reduction program targeting $3 million in annual savings and has paused new center openings. With $8.2 million in cash and operating cash flow of $11.4 million for 2024, AirSculpt has secured additional covenant relief from lenders to support its transformation efforts.